CORDUA, ALESSIA
 Distribuzione geografica
Continente #
EU - Europa 112
NA - Nord America 94
AS - Asia 69
SA - Sud America 32
AF - Africa 1
Totale 308
Nazione #
US - Stati Uniti d'America 90
IT - Italia 70
SG - Singapore 31
BR - Brasile 25
CN - Cina 14
DE - Germania 13
VN - Vietnam 10
FI - Finlandia 7
NL - Olanda 7
IN - India 6
GB - Regno Unito 5
CO - Colombia 3
AR - Argentina 2
AT - Austria 2
CZ - Repubblica Ceca 2
MX - Messico 2
RU - Federazione Russa 2
BD - Bangladesh 1
BO - Bolivia 1
CA - Canada 1
CH - Svizzera 1
ES - Italia 1
FR - Francia 1
HK - Hong Kong 1
ID - Indonesia 1
IQ - Iraq 1
IR - Iran 1
KZ - Kazakistan 1
LB - Libano 1
SE - Svezia 1
TR - Turchia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 308
Città #
San Jose 16
Carbonia 12
Munich 12
Singapore 12
Ashburn 10
Dallas 9
Chicago 7
Chandler 6
Ho Chi Minh City 6
Rome 6
Turku 6
Bengaluru 4
Ercolano 4
Hefei 4
London 4
Hanoi 3
Paola 3
Santa Clara 3
Afragola 2
Bologna 2
Delhi 2
Gesuiti 2
Reggio Calabria 2
San Nicola Manfredi 2
São Paulo 2
Alvorada 1
Astana 1
Balıkesir 1
Baturité 1
Beijing 1
Beirut 1
Benevento 1
Benito Juarez 1
Birmingham 1
Biên Hòa 1
Bragança Paulista 1
Brasília 1
Brooklyn 1
Caicó 1
Caldas Novas 1
Caseros 1
Catania 1
Chaguanas 1
Charlotte 1
Ciudad Bolívar 1
Cleveland 1
Cosenza 1
Crestview 1
Dolores Hidalgo 1
Helsinki 1
Hong Kong 1
Houston 1
Indian Trail 1
Isidro Casanova 1
Jacarezinho 1
Johannesburg 1
La Paz 1
Lajeado 1
Lawrence 1
Los Angeles 1
Madrid 1
Manaus 1
Medellín 1
Mocoa 1
Mosul 1
Naples 1
Niterói 1
Norwich 1
Nova Iguaçu 1
Nuremberg 1
Olomouc 1
Osasco 1
Padang 1
Palermo 1
Palotina 1
Petrópolis 1
Pittsburgh 1
Ponto Belo 1
Portland 1
Porto Alegre 1
Prague 1
Princeton 1
Salt Lake City 1
Salvador 1
Satuba 1
St Petersburg 1
Stockholm 1
São José do Rio Preto 1
Taubaté 1
Torres 1
Ubá 1
Vienna 1
Votuporanga 1
Zipaquirá 1
Totale 210
Nome #
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 110
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 93
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 76
A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer 39
Totale 318
Categoria #
all - tutte 1.543
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.543


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202214 0 0 0 0 0 0 0 0 9 5 0 0
2022/202318 2 1 1 0 4 3 0 1 2 3 1 0
2023/202432 15 3 4 1 1 3 0 0 0 0 3 2
2024/2025118 5 2 1 4 6 16 8 3 7 2 32 32
2025/2026136 9 15 20 19 19 4 17 9 13 11 0 0
Totale 318